Innovations in Precision Oncology: Biomarker-Driven Approaches for Enhanced Cancer Therapy.

Precision oncology is revolutionized by targeted therapies like talazoparib, a PARP inhibitor, leveraging advanced understanding of DNA repair mechanisms such as ribonucleotide excision repair and homologous recombination repair. CRISPR-Cas technology has been pivotal in unraveling these pathways, facilitating personalized treatment strategies. The identification of genomic loss of heterozygosity as a biomarker targets HRR-deficient cancers, enhancing talazoparib's efficacy. These breakthroughs represent a significant advancement in precision medicine, offering more effective, individualized cancer therapies.